Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer

A high baseline level of soluble human epidermal growth factor receptor 2 (sHER2) was a prognostic indicator of shorter disease-free survival among patients with early-stage HER2-positive breast cancer, according to results from the North Central Cancer Treatment Group adjuvant trial N9831.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news